A 6-gene Signature Identifies Four Molecular Subgroups of Neuroblastoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2011 Apr 16

PMID 21492432

Citations 19

Authors

Frida Abel

Daniel Dalevi

Maria Nethander

Rebecka Jornsten

Katleen De Preter

Joelle Vermeulen

Raymond Stallings

Per Kogner

John Maris

Staffan Nilsson

Affiliations

Soon will be listed here.

Abstract

Background: There are currently three postulated genomic subtypes of the childhood tumour neuroblastoma (NB); Type 1, Type 2A, and Type 2B. The most aggressive forms of NB are characterized by amplification of the oncogene MYCN (MNA) and low expression of the favourable marker NTRK1. Recently, mutations or high expression of the familial predisposition gene Anaplastic Lymphoma Kinase (ALK) was associated to unfavourable biology of sporadic NB. Also, various other genes have been linked to NB pathogenesis.

Results: The present study explores subgroup discrimination by gene expression profiling using three published microarray studies on NB (47 samples). Four distinct clusters were identified by Principal Components Analysis (PCA) in two separate data sets, which could be verified by an unsupervised hierarchical clustering in a third independent data set (101 NB samples) using a set of 74 discriminative genes. The expression signature of six NB-associated genes ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B, significantly discriminated the four clusters (p < 0.05, one-way ANOVA test). PCA clusters p1, p2, and p3 were found to correspond well to the postulated subtypes 1, 2A, and 2B, respectively. Remarkably, a fourth novel cluster was detected in all three independent data sets. This cluster comprised mainly 11q-deleted MNA-negative tumours with low expression of ALK, BIRC5, and PHOX2B, and was significantly associated with higher tumour stage, poor outcome and poor survival compared to the Type 1-corresponding favourable group (INSS stage 4 and/or dead of disease, p < 0.05, Fisher's exact test).

Conclusions: Based on expression profiling we have identified four molecular subgroups of neuroblastoma, which can be distinguished by a 6-gene signature. The fourth subgroup has not been described elsewhere, and efforts are currently made to further investigate this group's specific characteristics.

Citing Articles

Predicting Neuroblastoma Patient Risk Groups, Outcomes, and Treatment Response Using Machine Learning Methods: A Review.

Jahangiri L Med Sci (Basel). 2024; 12(1).

PMID: 38249081 PMC: 10801560. DOI: 10.3390/medsci12010005.

Diagnostic classification of childhood cancer using multiscale transcriptomics.

Comitani F, Nash J, Cohen-Gogo S, Chang A, Wen T, Maheshwari A Nat Med. 2023; 29(3):656-666.

PMID: 36932241 PMC: 10033451. DOI: 10.1038/s41591-023-02221-x.

Unsupervised Algorithms for Microarray Sample Stratification.

Fratello M, Cattelani L, Federico A, Pavel A, Scala G, Serra A Methods Mol Biol. 2021; 2401:121-146.

PMID: 34902126 DOI: 10.1007/978-1-0716-1839-4_9.

MYCN in Neuroblastoma: "Old Wine into New Wineskins".

Braoudaki M, Hatziagapiou K, Zaravinos A, Lambrou G Diseases. 2021; 9(4).

PMID: 34842635 PMC: 8628738. DOI: 10.3390/diseases9040078.

Neuronal lineages derived from the nerve-associated Schwann cell precursors.

Kameneva P, Kastriti M, Adameyko I Cell Mol Life Sci. 2020; 78(2):513-529.

PMID: 32748156 PMC: 7873084. DOI: 10.1007/s00018-020-03609-5.

References

Cheung I, Feng Y, Vickers A, Gerald W, Cheung N . Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn. 2007; 9(2):237-41. PMC: 1867438. DOI: 10.2353/jmoldx.2007.060130. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Ambros P, Ambros I, Strehl S, Bauer S, Luegmayr A, Kovar H . Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?. Eur J Cancer. 1995; 31A(4):510-5. DOI: 10.1016/0959-8049(95)00044-j. View

Thorell K, Bergman A, Caren H, Nilsson S, Kogner P, Martinsson T . Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics. 2009; 2:53. PMC: 2743704. DOI: 10.1186/1755-8794-2-53. View

Albino D, Scaruffi P, Moretti S, Coco S, Truini M, Di Cristofano C . Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer. 2008; 113(6):1412-22. DOI: 10.1002/cncr.23720. View

Wilzen A, Nilsson S, Sjoberg R, Kogner P, Martinsson T, Abel F . The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol. 2009; 34(3):697-705. DOI: 10.3892/ijo_00000196. View

Panagopoulos I, Lilljebjorn H, Strombeck B, Hjorth L, Olofsson T, Johansson B . MLL/GAS7 fusion in a pediatric case of t(11;17)(q23;p13)-positive precursor B-cell acute lymphoblastic leukemia. Haematologica. 2006; 91(9):1287-8. View

Leon T, Ngan E, Poon H, So M, Lui V, Tam P . Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3. J Pediatr Surg. 2009; 44(10):1904-12. DOI: 10.1016/j.jpedsurg.2008.11.055. View

Look A, Hayes F, Shuster J, Douglass E, Castleberry R, Bowman L . Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991; 9(4):581-91. DOI: 10.1200/JCO.1991.9.4.581. View

10.

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

11.

Eckerle I, Muth D, Batzler J, Henrich K, Lutz W, Fischer M . Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett. 2009; 285(1):99-107. DOI: 10.1016/j.canlet.2009.05.007. View

12.

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D . Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006; 66(12):6050-62. DOI: 10.1158/0008-5472.CAN-05-4618. View

13.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout E . Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010; 16(17):4353-62. DOI: 10.1158/1078-0432.CCR-09-2660. View

14.

Fischer M, Bauer T, Oberthur A, Hero B, Theissen J, Ehrich M . Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene. 2009; 29(6):865-75. DOI: 10.1038/onc.2009.390. View

15.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

16.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y . Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010; 28(21):3506-15. DOI: 10.1200/JCO.2009.27.3367. View

17.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

18.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J . Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10(7):663-71. PMC: 3045079. DOI: 10.1016/S1470-2045(09)70154-8. View

19.

Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg R, Abrahamsson J . High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics. 2008; 9:353. PMC: 2527340. DOI: 10.1186/1471-2164-9-353. View

20.

George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J . Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. PMC: 2587486. DOI: 10.1038/nature07397. View